FourThought Financial Partners LLC Trims Position in Illumina, Inc. (NASDAQ:ILMN)

FourThought Financial Partners LLC trimmed its position in Illumina, Inc. (NASDAQ:ILMN) by 24.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 17,231 shares of the life sciences company’s stock after selling 5,589 shares during the period. FourThought Financial Partners LLC’s holdings in Illumina were worth $2,399,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in ILMN. Annis Gardner Whiting Capital Advisors LLC purchased a new position in shares of Illumina in the third quarter worth approximately $30,000. VisionPoint Advisory Group LLC grew its holdings in Illumina by 344.6% during the third quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock valued at $34,000 after purchasing an additional 193 shares during the period. Wetzel Investment Advisors Inc. bought a new position in shares of Illumina in the fourth quarter worth about $37,000. Gradient Investments LLC lifted its holdings in Illumina by 375.0% during the fourth quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock valued at $40,000 after purchasing an additional 225 shares in the last quarter. Finally, North Star Investment Management Corp. raised its holdings in Illumina by 183.0% during the fourth quarter. North Star Investment Management Corp. now owns 300 shares of the life sciences company’s stock valued at $42,000 after acquiring an additional 194 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on ILMN. HSBC downgraded Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. Barclays boosted their price objective on shares of Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a research report on Wednesday, April 10th. StockNews.com lowered Illumina from a “buy” rating to a “hold” rating in a report on Friday. OTR Global reaffirmed a “mixed” rating on shares of Illumina in a research note on Wednesday, March 20th. Finally, Stephens reissued an “overweight” rating and set a $170.00 target price on shares of Illumina in a research report on Wednesday, April 10th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, Illumina has an average rating of “Hold” and a consensus price target of $165.10.

Insider Transactions at Illumina

In other news, CEO Jacob Thaysen purchased 7,330 shares of the stock in a transaction that occurred on Thursday, February 22nd. The shares were purchased at an average cost of $135.29 per share, with a total value of $991,675.70. Following the completion of the acquisition, the chief executive officer now owns 14,861 shares of the company’s stock, valued at approximately $2,010,544.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.17% of the company’s stock.

Illumina Stock Performance

NASDAQ ILMN traded down $6.06 on Friday, hitting $117.93. 2,987,105 shares of the company’s stock traded hands, compared to its average volume of 1,375,095. The firm has a market capitalization of $18.78 billion, a PE ratio of -14.47 and a beta of 1.20. Illumina, Inc. has a 1-year low of $89.00 and a 1-year high of $213.91. The firm’s 50-day moving average price is $130.03 and its two-hundred day moving average price is $127.02. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.26.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.05. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.28%. The company had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.05 billion. During the same period in the previous year, the firm posted $0.08 earnings per share. The firm’s quarterly revenue was down 1.0% on a year-over-year basis. As a group, analysts expect that Illumina, Inc. will post 0.91 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.